MX2021011242A - Conjugados de vesícula extracelular y usos de estos. - Google Patents

Conjugados de vesícula extracelular y usos de estos.

Info

Publication number
MX2021011242A
MX2021011242A MX2021011242A MX2021011242A MX2021011242A MX 2021011242 A MX2021011242 A MX 2021011242A MX 2021011242 A MX2021011242 A MX 2021011242A MX 2021011242 A MX2021011242 A MX 2021011242A MX 2021011242 A MX2021011242 A MX 2021011242A
Authority
MX
Mexico
Prior art keywords
extracellular vesicle
extracellular vesicles
extracellular
methods
vesicle conjugates
Prior art date
Application number
MX2021011242A
Other languages
English (en)
Inventor
Sriram Sathyanarayanan
Russell E Mcconell
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MX2021011242A publication Critical patent/MX2021011242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se relaciona con vesículas extracelulares (por ejemplo, exosomas) que comprenden una molécula biológicamente activa unidas de forma covalente a la vesícula extracelular mediante un resto maleimida, que puede ser útil como agente para la profilaxis o tratamiento del cáncer y otras enfermedades. También se proporcionan en la presente métodos para producir las vesículas extracelulares y métodos para usar las vesículas extracelulares para tratar enfermedades o trastornos.
MX2021011242A 2019-03-21 2020-03-20 Conjugados de vesícula extracelular y usos de estos. MX2021011242A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962822014P 2019-03-21 2019-03-21
US201962835439P 2019-04-17 2019-04-17
PCT/US2020/024057 WO2020191377A1 (en) 2019-03-21 2020-03-20 Extracellular vesicle conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2021011242A true MX2021011242A (es) 2022-01-19

Family

ID=70296048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011242A MX2021011242A (es) 2019-03-21 2020-03-20 Conjugados de vesícula extracelular y usos de estos.

Country Status (11)

Country Link
US (1) US20240108747A1 (es)
EP (1) EP3941528A1 (es)
JP (1) JP2022525924A (es)
KR (1) KR20210141554A (es)
CN (1) CN113747925A (es)
AU (1) AU2020241903A1 (es)
CA (1) CA3133314A1 (es)
IL (1) IL286562A (es)
MX (1) MX2021011242A (es)
SG (1) SG11202109587TA (es)
WO (1) WO2020191377A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544288A (ja) * 2019-08-14 2022-10-17 コディアック バイオサイエンシーズ， インコーポレイテッド ＣＥＢＰ／βを標的とする細胞外小胞－ＡＳＯ構築物
CN114829586A (zh) * 2019-08-14 2022-07-29 科迪亚克生物科学公司 细胞外囊泡-nlrp3拮抗剂
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
KR102525384B1 (ko) * 2020-12-17 2023-04-24 인천대학교 산학협력단 이중 약물이 봉입된 세포외 소포체의 제조방법
CN112662695B (zh) * 2020-12-30 2021-11-26 中国医学科学院医学生物学研究所 一种细菌生物膜囊泡bbv作为疫苗载体的构建方法和应用
KR20230157346A (ko) * 2021-02-17 2023-11-16 론자 세일즈 아게 세포외 소포체를 로딩하는 방법
CA3207947A1 (en) * 2021-02-17 2022-08-25 Aaron Noyes Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
WO2022256201A1 (en) * 2021-06-03 2022-12-08 The Board Of Trustees Of The Leland Stanford Junior University Engineered bmp2 surrogate proteins
CA3228747A1 (en) * 2021-08-19 2023-02-23 Young Jik Kwon Antigen presenting cell/target cell hybridoma-derived vaccines
WO2023056468A1 (en) * 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
WO2023205702A2 (en) * 2022-04-20 2023-10-26 The Board Of Trustees Of The University Of Illinois Modified exosomes and methods of use
WO2024040075A1 (en) * 2022-08-17 2024-02-22 Lonza Sales Ag Extracellular vesicle comprising a biologically active molecule and a dual cleavable linker
WO2024040073A1 (en) * 2022-08-17 2024-02-22 Lonza Sales Ag Extracellular vesicle comprising a biologically active molecule and a cleavable linker
WO2024040076A1 (en) * 2022-08-17 2024-02-22 Lonza Sales Ag Extracellular vesicle comprising a biologically active molecule and a cell penetratng peptide cleavable linker
WO2024039896A1 (en) * 2022-08-19 2024-02-22 Northeastern University Cationic peptide/protein-modified exosomes for applications in drug delivery

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
DE04020014T1 (de) 1997-09-12 2006-01-26 Exiqon A/S Bi-zyklische - Nukleosid,Nnukleotid und Oligonukleotid-Analoga
EP1152009B2 (en) 1999-02-12 2017-09-06 Daiichi Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US7087386B2 (en) 1999-06-11 2006-08-08 The Burnham Institute Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP2141233B1 (en) 2002-11-18 2016-10-19 Roche Innovation Center Copenhagen A/S Antisense design
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060269480A1 (en) 2005-05-31 2006-11-30 Ramot At Tel Aviv University Ltd. Multi-triggered self-immolative dendritic compounds
KR20130042043A (ko) 2006-01-27 2013-04-25 아이시스 파마수티컬즈 인코포레이티드 6-변형된 바이시클릭 핵산 유사체
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
CN102614528B (zh) 2006-08-18 2014-02-26 箭头研究公司 用于体内递送多核苷酸的多缀合物
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
PL2510946T3 (pl) 2007-02-07 2015-12-31 Univ California Koniugaty syntetycznych agonistów tlr i ich zastosowania
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
CA2695991A1 (en) * 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
US9421254B2 (en) 2007-09-24 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunostimulatory combinations of TLR ligands and methods of use
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US8242106B2 (en) 2008-08-01 2012-08-14 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US20120178710A1 (en) 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
FR2950350B1 (fr) 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
EA021842B1 (ru) 2009-10-06 2015-09-30 Общество С Ограниченной Ответственностью "Панацела Лабс" Применение toll-подобного рецептора и агониста для лечения рака
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CN103153335A (zh) 2010-06-30 2013-06-12 布兰代斯大学 小分子靶定的蛋白质降解
ES2616449T3 (es) 2010-10-01 2017-06-13 Ventirx Pharmaceuticals, Inc. Uso terapéutico de un agonista de TLR y terapia de combinación
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
US20150119435A1 (en) 2012-05-11 2015-04-30 Yale University Compounds useful for promoting protein degradation and methods using same
JP6257607B2 (ja) 2012-06-08 2018-01-10 アデュロ バイオテック，インコーポレイテッド 癌免疫療法のための組成物および方法
WO2014043544A1 (en) 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9115184B2 (en) 2013-03-01 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Light-inducible system for regulating protein stability
US20140255361A1 (en) 2013-03-07 2014-09-11 The Board Of Trustees Of The Leland Stanford Junior University Estrogen-receptor based ligand system for regulating protein stability
TN2015000457A1 (en) 2013-04-29 2017-04-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US20140329889A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
AU2014268836B2 (en) 2013-05-18 2018-08-02 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CA2907960C (en) 2013-05-22 2021-10-19 Children's Hospital Medical Center Combination therapy for mds
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
KR20170015353A (ko) 2014-06-04 2017-02-08 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Ｓｔｉｎｇ의 조절제로서 사이클릭 디­뉴클레오타이드
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
PL3233882T3 (pl) 2014-12-16 2020-04-30 Kayla Therapeutics Fluorowane cykliczne dinukleotydy do indukcji cytokin
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
MX2017011919A (es) 2015-03-18 2018-05-22 Arvinas Inc Compuestos y metodos para la degradacion mejorada de proteinas especificas.
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016291578C1 (en) 2015-07-10 2021-07-15 Arvinas Operations, Inc. MDM2-based modulators of proteolysis and associated methods of use
RU2018105094A (ru) 2015-07-13 2019-08-14 Арвинас, Инк. Модуляторы протеолиза на основе аланина и связанные с ними способы применения
GB201512733D0 (en) * 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2995036A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
UA123701C2 (uk) 2015-08-13 2021-05-19 Мерк Шарп І Доум Корп. Циклічні динуклеотидні сполуки як агоністи sting
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
MX2018005299A (es) 2015-10-28 2019-03-18 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon".
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
US11008372B2 (en) 2015-11-07 2021-05-18 Board Of Regents, The University Of Texas System Targeting proteins for degradation
US20190016703A1 (en) 2015-12-30 2019-01-17 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
US20200216454A1 (en) 2015-12-30 2020-07-09 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for her3 degradation and methods of use
WO2017137477A1 (en) * 2016-02-09 2017-08-17 Bracco Suisse Sa A recombinant chimeric protein for selectins targeting
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
RU2018137389A (ru) 2016-04-07 2020-05-12 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Гетероциклические амиды, полезные в качестве модуляторов
IL295649A (en) 2016-04-07 2022-10-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides are useful as protein modulators
CA3020792A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
CA3018429A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
CA3021358A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
US10865204B2 (en) 2016-04-22 2020-12-15 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
CA3020543A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 8 (cdk8) by conjugation of cdk8 inhibitors with e3 ligase ligand and methods of use
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
AU2017266929B2 (en) * 2016-05-18 2023-05-11 Modernatx, Inc. Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201610156D0 (en) 2016-06-10 2016-07-27 Otsuka Pharma Co Ltd Cliptac compositions
AU2017281903B2 (en) 2016-06-23 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
GB201614134D0 (en) 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
IL304982A (en) 2016-11-01 2023-10-01 Arvinas Operations Inc PROTACS Targeted Tau-Protein and Related Methods of Use
WO2018085247A1 (en) 2016-11-01 2018-05-11 Cornell University Compounds for malt1 degradation
WO2018089736A1 (en) 2016-11-10 2018-05-17 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
JP2019535746A (ja) 2016-11-22 2019-12-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用法
AU2017363252B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
EP3548483A4 (en) 2016-12-01 2020-06-10 Arvinas Operations, Inc. TETRAHYDRONAPHTHALINE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS AN ESTROGEN RECEPTOR-DEGRADING AGENT
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
CA3045037A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
WO2019040920A1 (en) 2017-08-25 2019-02-28 Codiak Biosciences, Inc. PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
CN107913408A (zh) * 2017-11-16 2018-04-17 中南大学 一种外泌体‑核酸适配体脂质体复合载药***及其制备方法和应用
CN110227162A (zh) * 2019-05-15 2019-09-13 清华-伯克利深圳学院筹备办公室 靶向外泌体及制备方法、应用、药物递送***和药物

Also Published As

Publication number Publication date
JP2022525924A (ja) 2022-05-20
KR20210141554A (ko) 2021-11-23
AU2020241903A1 (en) 2021-10-14
US20240108747A1 (en) 2024-04-04
CN113747925A (zh) 2021-12-03
SG11202109587TA (en) 2021-10-28
CA3133314A1 (en) 2020-09-24
EP3941528A1 (en) 2022-01-26
IL286562A (en) 2021-10-31
WO2020191377A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MX2021011242A (es) Conjugados de vesícula extracelular y usos de estos.
MX2022001770A (es) Vesícula extracelular unida a moléculas y usos de esta.
MX2020002806A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso.
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
HK1157337A1 (es)
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.
CR20140267A (es) Metodos para tratar transtornos relacionados con mutante viii de eliminacion de factor de crecimiento epidérmico
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
BRPI0917245A8 (pt) Compostos derivados de isoquinolinona e sua composição farmacêutica
MX2020003089A (es) Analogos de tailanstatina.
MX2008002065A (es) Derivados de pirazola como agentes terapeuticos.
TW200734324A (en) Therapeutic agents
WO2022066898A3 (en) Methods of producing extracellular vesicles
MX2022000450A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
MX2022015630A (es) Composiciones y metodos para el tratamiento de enfermedades y trastornos usando vesiculas extracelulares microbianas de oscillospiraceae.
MX2023000945A (es) 55cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias.
MX2022013396A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments